Scott C Garman

US Patent:

20030003502, Jan 2, 2003

Filed:

Mar 14, 2001

Appl. No.:

09/809715

Inventors:

Theodore Jardetzky - Chicago IL, US
Scott Garman - Rockville MD, US
Beth Wurzburg - Evanston IL, US
Jean-Pierre Kinet - Lexington MA, US

International Classification:

G01N033/53
G06G007/48
G06G007/58
G06F019/00

US Classification:

435/007100, 702/019000, 703/011000

Abstract:

The present invention includes three-dimensional models of complexes between antibody receptor proteins, such as Fc RI proteins, and antibodies, such as Fc-C 3/C 4 regions of IgE antibodies, as well as methods to produce such models. The present invention also includes muteins having increased stability and/or antibody binding activity, as well as methods to produce such muteins, preferably using information derived from three-dimensional models of the present invention. Also included are nucleic acid sequences encoding muteins of the present invention and use of those sequences to produce such muteins. Also included is the use of the model to identify compounds that inhibit the binding of an antibody receptor protein to an antibody. The present invention also includes uses of such muteins and inhibitory compounds, for example, in methods to diagnose and protect animals from allergy and other abnormal immune responses.

US Patent:

20040033527, Feb 19, 2004

Filed:

Nov 13, 2002

Appl. No.:

10/293992

Inventors:

Theodore Jardetzky - Chicago IL, US
Scott Garman - Evanston IL, US
Jean-Pierre Kinet - Lexington MA, US

International Classification:

G01N033/53
G06G007/48
G06G007/58

US Classification:

435/007100, 703/011000

Abstract:

The present invention includes three-dimensional models of antibody receptor proteins, such as Fc RI proteins, and methods to produce such models. The present invention also includes muteins having increased stability and/or antibody binding activity, as well as methods to produce such muteins, preferably using information derived from three-dimensional models of the present invention. Also included are nucleic acid sequences encoding muteins of the present invention and use of those sequences to produce such muteins. Also included is the use of the model to identify compounds that inhibit the binding of an antibody receptor protein to an antibody. The present invention also includes uses of such muteins and inhibitory compounds, for example, in methods to diagnose and protect animals from allergy and other abnormal immune responses.

US Patent:

20060036420, Feb 16, 2006

Filed:

Jul 19, 2005

Appl. No.:

11/184147

Inventors:

Theodore Jardetzky - Chicago IL, US
Scott Garman - Rockville MD, US
Beth Wurzburg - Evanston IL, US
Jean-Pierre Kinet - Lexington MA, US

International Classification:

G06G 7/48
G06G 7/58

US Classification:

703011000

Abstract:

The present invention includes three-dimensional models of complexes between antibody receptor proteins, such as FcεRIα proteins, and antibodies, such as Fc-Cε3/Cε4 regions of IgE antibodies, as well as methods to produce such models. The present invention also includes muteins having increased stability and/or antibody binding activity, as well as methods to produce such muteins, preferably using information derived from three-dimensional models of the present invention. Also included are nucleic acid sequences encoding muteins of the present invention and use of those sequences to produce such muteins. Also included is the use of the model to identify compounds that inhibit the binding of an antibody receptor protein to an antibody. The present invention also includes uses of such muteins and inhibitory compounds, for example, in methods to diagnose and protect animals from allergy and other abnormal immune responses.

US Patent:

20170333363, Nov 23, 2017

Filed:

Sep 17, 2015

Appl. No.:

15/508955

Inventors:

- Boston MA, US
Mijanur Rahaman Molla - Amherst MA, US
Scott Clayton Garman - Amherst MA, US

Assignee:

University of Massachusetts - Boston MA

International Classification:

A61K 9/51
A61K 9/06
A61K 31/713
C08F 120/28

Abstract:

The invention provides pH- or redox-responsive and charge-neutral polymeric nanogels that stably encapsulate a biomolecule at one pH or redox condition and then release it at a different pH or redox condition, and compositions and methods of preparation and use thereof.